Adults 18 to 40, any sex, with Autism or Autistic Traits or Mental Health Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Depression_1Primary· Pre-test (baseline), Post-test (immediately after the intervention)
Depression Anxiety Stress Scale 21 will be used to measure depression outcome. Higher scores mean higher depressive symptoms. The minimum and maximum scores are 0-21, respectively.
Pretest
Group
Value
95% CI
Experimental Group
9.87
± 3.72
Control Group
10.24
± 4.02
Posttest
Group
Value
95% CI
Experimental Group
7.65
± 2.57
Control Group
9.15
± 4.13
AnxietyPrimary· Pre-test (baseline), Post-test (immediately after the intervention)
Depression Anxiety Stress Scale - 21 will be used to measure anxiety outcome. Higher scores mean higher anxiety symptoms. The minimum and maximum scores are 0-21, respectively.
Pretest
Group
Value
95% CI
Experimental Group
9.42
± 3.70
Control Group
9.44
± 3.94
Posttest
Group
Value
95% CI
Experimental Group
6.74
± 2.94
Control Group
8.03
± 4.20
StressPrimary· Pre-test (baseline), Post-test (immediately after the intervention)
Depression Anxiety Stress Scale - 21 will be used to measure stress outcome. Higher scores indicate higher stress. The minimum and maximum scores are 0-21, respectively.
Pretest
Group
Value
95% CI
Experimental Group
7.61
± 3.98
Control Group
6.32
± 3.98
Posttest
Group
Value
95% CI
Experimental Group
5.58
± 3.56
Control Group
7.79
± 4.05
Cognitive Flexibility - Errors RatePrimary· Pre-test (baseline), Post-test (immediately after the intervention)
Cognitive flexibility - Errors Rate will be measured by the Wisconsin Card Sorting Task. Higher errors indicate lower scores on cognitive flexibility. During the task, 400 cards in two blocks are displayed on the screen and the sorting rule changes after every 10 cards. Maximum score is 400 and minimum score is 0.
Pretest
Group
Value
95% CI
Experimental Group
21
± 10
Control Group
22
± 4
Posttest
Group
Value
95% CI
Experimental Group
40
± 20
Control Group
37
± 15
Working Memory - Errors RatePrimary· Pre-test (baseline), Post-test (immediately after the intervention)
Working memory - Errors Rate will be measured by the N-back task. Higher errors indicate lower working memory scores. Maximum score is 400, minimum score is 0
Pretest
Group
Value
95% CI
Experimental Group
20.65
± 9.19
Control Group
15.09
± 11.94
Posttest
Group
Value
95% CI
Experimental Group
13.13
± 8.59
Control Group
10.50
± 7.55
Inhibition - Errors RatePrimary· Pre-test (baseline), Post-test (immediately after the intervention)
Inhibition - Errors Rate will be measured by Go/No Go task. Higher scores indicate lower inhibition. There are 12 blocks of 50 trials each. Commission errors (i.e., incorrectly responding to no-go trials) were measured. Maximum score is 600. Minimum score is 0.
Pretest
Group
Value
95% CI
Experimental Group
5.48
± 6.59
Control Group
3.24
± 5.18
Posttest
Group
Value
95% CI
Experimental Group
4.48
± 3.37
Control Group
3.85
± 3.21
Cognitive EmpathySecondary· pretest and posttest conditions
The Eyes Test were used to measure cognitive empathy. Higher scores indicate higher cognitive empathy scores. Maximum score is 36, minimum score is 0.
Pretest
Group
Value
95% CI
Experimental Group
24.45
± 3.88
Control Group
25.65
± 3.27
Posttest
Group
Value
95% CI
Experimental Group
25.39
± 4.29
Control Group
26.59
± 3.44
Self-Assessment Manikin for Affective EmpathySecondary· pretest and posttest conditions
Self Assessment Manikin was used to measure affective empathy. Valence scores for each emotion were obtained by summing responses for all images. The maximum score is 270, and the minimum score is 30. Higher scores indicate better affective empathy.
Pretest
Group
Value
95% CI
Experimental Group
130.16
± 20.43
Control Group
119.35
± 16.88
Posttest
Group
Value
95% CI
Experimental Group
126.16
± 12.90
Control Group
117.38
± 16.61
Sponsor's own description
The objective of this study is to analyze the effects of executive functions (EFs) and social-cognitive abilities on the associations between autistic traits and mental health indicators (depression, anxiety, and stress). Moreover, the study will produce online training modules for executive functions and social cognition, aimed at reducing the likelihood of adverse mental health outcomes in individuals with and without elevated autistic traits.
Therefore, four main hypotheses will be addressed:
1. Revealing the mediating role of executive functions (cognitive flexibility, inhibitory control, and working memory) will help predict the association between autistic traits and mental health symptoms (anxiety, depression, and stress).
2. Revealing the mediating role of social cognitive skills (cognitive empathy and affective empathy) will help predict the association between autistic traits and mental health symptoms (anxiety, depression, and stress).
3. Online training in executive functions and social cognitive skills will help develop executive functions (working memory, inhibitory control, and cognitive flexibility) and social cognitive skills (cognitive empathy and affective empathy) in the current sample.
4. Online training in executive functions and social cognitive skills will promote mental health by reducing distress, depression, and anxiety symptoms in the current sample.
Participants will be between the ages of 18-35 because previous findings indicate that the age of onset of various mental health problems is between the ages of 17 and 35. Participants will be randomly assigned to the experimental and control groups. Using a longitudinal design including pre-test, post-test, and follow-up conditions to test the effectiveness of combined EFs and social cognition online training for mental health symptoms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Other recruiting trials for Autism or Autistic Traits
Currently open trials in the same condition.
NCT06698588 — Symptom-specific Effects of Omega-3 Across Neurodevelopmental Symptoms
· NA
· recruiting
NCT06399952 — Baker Gordon Syndrome Natural History Study
· recruiting
NCT06329245 — Development of Prosocial Behaviors and Related Brain Network in Infants of High and Low Risk of ASD
· recruiting
NCT06495684 — Effects of Multiple-Session Transcranial Direct Current Stimulation (tDCS) on Behavioral, Physiological, and Electrophys
· NA
· recruiting
NCT05663970 — Virtual Group Social ABCs - Multi-site Randomized Controlled Trial
· NA
· active not recruiting
Other Ibn Haldun University trials
Trials by the same sponsor.
NCT07008209 — Comparing the Effectiveness of Reappraisal Strategies in Adult Participants
· NA
· completed
NCT06876103 — Effectiveness of an Online Religiously-integrated Cognitive Behavioral Therapy-based Intervention on Death Anxiety
· NA
· not yet recruiting
NCT06945796 — ACT-ED: Accessibility and Feasibility of an Acceptance and Commitment Therapy (ACT)-Based Eating Disorder Prevention Pro
· NA
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ibn Haldun University
Last refreshed: 17 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06213194.